Premier Biomedical Inc (BIEI) Financial Statements (2024 and earlier)

Company Profile

Business Address P.O. BOX 25
JACKSON CENTER, PA 16133
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1178781876310
Cash and cash equivalents1178781876310
Receivables32232 
Inventory, net of allowances, customer advances and progress billings21222426119123
Inventory21222426119123
Other current assets363540443836
Total current assets:178147148160222170
Noncurrent Assets
Property, plant and equipment897566
Total noncurrent assets:897566
TOTAL ASSETS:186155155165228176
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities242264294286329361
Interest and dividends payable493926222214
Accounts payable193225268264307348
Debt192250253310304218
Due to related parties313230263137
Other undisclosed current liabilities1,8391,7531,5511,6901,8081,586
Total current liabilities:2,3042,2982,1282,3122,4722,203
Noncurrent Liabilities
Total liabilities:2,3042,2982,1282,3122,4722,203
Equity
Equity, attributable to parent, including:(2,118)(2,143)(1,973)(2,147)(2,244)(2,027)
Preferred stock   222
Common stock000000
Common stock, value, subscriptions   7   
Additional paid in capital14,94714,74114,67814,57313,96813,833
Accumulated deficit(17,068)(16,886)(16,659)(16,728)(16,226)(15,862)
Other undisclosed equity, attributable to parent222513 
Total equity:(2,118)(2,143)(1,973)(2,147)(2,244)(2,027)
TOTAL LIABILITIES AND EQUITY:186155155165228176

Income Statement (P&L) ($ in thousands)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues3469812
Cost of revenue(2)(2)(2)(93)(4)(10)
Gross profit:224(84)42
Operating expenses(66)(75)(86)(378)(85)(82)
Operating loss:(65)(73)(82)(462)(81)(80)
Nonoperating income (expense)(117)(154)151(40)(282)(20)
Interest and debt expense(56)(38)(8)(93)(185)(74)
Income (loss) from continuing operations:(238)(265)61(595)(548)(174)
Income (loss) before gain (loss) on sale of properties:(238)(265)61(595)(548)(174)
Net income (loss):(238)(265)61(595)(548)(174)
Other undisclosed net income attributable to parent563889318574
Net income (loss) available to common stockholders, diluted:(182)(227)69(502)(364)(100)

Comprehensive Income ($ in thousands)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net income (loss):(238)(265)61(595)(548)(174)
Comprehensive income (loss), net of tax, attributable to parent:(238)(265)61(595)(548)(174)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: